Amphastar Pharmaceuticals (NASDAQ:AMPH) Announces Earnings Results, Misses Expectations By $0.24 EPS

Amphastar Pharmaceuticals (NASDAQ:AMPH) posted its quarterly earnings data on Thursday. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.24), FiscalAI reports. The business had revenue of $183.11 million during the quarter, compared to analyst estimates of $190.48 million. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%.

Here are the key takeaways from Amphastar Pharmaceuticals’ conference call:

• FDA approved Ipratropium Bromide HFA (AMP-007)
• BAQSIMI remained a key contributor (2025 revenue $185.4M, +12% YoY); management expects mid-single-digit U.S. unit growth in 2026 while exiting a handful of unprofitable international markets later in the year.
• Full-year revenue was $719.9M (down 2%) as legacy products faced steep pricing pressure — glucagon fell sharply (Q4 -45%) and epinephrine declined — and management expects lower gross margins in 2026.
• Pipeline progress includes three novel peptides and a fully synthetic corticotropin, plus high‑value near/midterm programs (AMP-004 insulin aspart BLA and AMP-018 GLP-1 ANDA) targeting commercialization in 2027, supporting long-term value creation.
• Management is investing to quadruple U.S. manufacturing capacity in Rancho Cucamonga, intends to fund expansion from operations, holds over $300M of cash, and will balance additional buybacks with business‑development opportunities.

Amphastar Pharmaceuticals Trading Down 23.6%

Shares of NASDAQ AMPH traded down $6.26 during midday trading on Friday, reaching $20.23. The company had a trading volume of 1,965,411 shares, compared to its average volume of 397,544. The stock has a market cap of $929.61 million, a PE ratio of 8.95, a price-to-earnings-growth ratio of 5.10 and a beta of 0.88. Amphastar Pharmaceuticals has a one year low of $19.83 and a one year high of $31.26. The firm’s fifty day moving average price is $27.36 and its 200-day moving average price is $27.06. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 9,787 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $26.20, for a total value of $256,419.40. Following the completion of the sale, the executive vice president owned 138,043 shares in the company, valued at approximately $3,616,726.60. This trade represents a 6.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Floyd F. Petersen sold 2,426 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $25.92, for a total value of $62,881.92. Following the transaction, the director owned 71,368 shares of the company’s stock, valued at approximately $1,849,858.56. This represents a 3.29% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 13,950 shares of company stock worth $363,925. Insiders own 27.50% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMPH. Occudo Quantitative Strategies LP purchased a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $362,000. PDT Partners LLC bought a new stake in Amphastar Pharmaceuticals in the 2nd quarter worth approximately $336,000. Quantinno Capital Management LP bought a new stake in Amphastar Pharmaceuticals in the 2nd quarter worth approximately $259,000. Franklin Resources Inc. purchased a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at $254,000. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 11.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 8,742 shares of the company’s stock valued at $234,000 after buying an additional 882 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analysts Set New Price Targets

AMPH has been the subject of several research analyst reports. Wells Fargo & Company dropped their price target on Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating for the company in a report on Friday. Barclays began coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 target price for the company. Zacks Research lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Needham & Company LLC dropped their price objective on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Friday. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $29.50.

More Amphastar Pharmaceuticals News

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Management expects mid- to high-single-digit revenue growth for 2026 and is launching a new respiratory product, which provides a clear growth runway beyond the quarter that disappointed investors. Amphastar outlines mid- to high-single-digit revenue growth for 2026 while launching new respiratory product
• Positive Sentiment: Two sell-side shops lowered price targets from $34 to $30 but retained constructive ratings (Wells Fargo: overweight; Needham: buy), signaling that analysts still see significant upside from current levels despite trimming near-term assumptions. Analyst price target coverage
• Neutral Sentiment: Company published its Q4 press release, slide deck and conference call materials for investors to review detailed results and management commentary. These materials may clarify margin drivers and product cadence. Press release / slide deck
• Neutral Sentiment: Analyst and media write-ups (Zacks, Seeking Alpha, Investing.com) provide deeper metric-level analysis comparing results to estimates — useful for modeling but not new catalyst by itself. Zacks comparison of key metrics
• Negative Sentiment: Q4 results missed consensus: adjusted EPS of $0.73 vs. ~$0.97 expected and revenue of $183.1M vs. ~$190.5M, prompting investor concern about near-term growth and profit leverage. MarketBeat earnings summary
• Negative Sentiment: Market reaction has been amplified by heavy trading and coverage noting the miss; short-interest reports in public feeds are noisy/unclear but the immediate selloff reflects disappointment with the quarter. Yahoo finance: earnings miss and market reaction

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.

Read More

• Five stocks we like better than Amphastar Pharmaceuticals
• The gold chart Wall Street is terrified of…
• America’s 1776 happening again
• This makes me furious
• Buy this Gold Stock Before May 2026
• What a Former CIA Agent Knows About the Coming Collapse